logo
New Details On F/A-18 Super Hornet's Troubled IRST Pod

New Details On F/A-18 Super Hornet's Troubled IRST Pod

Yahooa day ago

More details have emerged about the problems the U.S. Navy is facing with its ill-starred podded Infrared Search And Track system, or IRST, an important capability planned for its F/A-18E/F Super Hornet fighters. The latest issues to be highlighted come after TWZ previously reported on delays caused by production quality problems with the system and a Pentagon assessment of 'significant reliability problems during operational testing,' which emerged earlier this year.
The latest status update on the ASG-34A(V)1 IRST pod is provided in the Weapon Systems Annual Assessment that was published today by the Government Accountability Office (GAO).
The centerline-mounted IRST pod is intended to provide the F/A-18E/F with a long-wave infrared sensor — the Lockheed Martin-developed IRST21 — that can search, detect, and track airborne targets. Very importantly, it is an ideal tool for detecting stealthy targets, which are proliferating. The IRST sensor assembly is installed in the front portion of a redesigned FPU-13/A centerline fuel tank. According to the GAO, each pod costs $16.6 million. For the full background on the pod, you can read our interview with the Super Hornet program manager responsible for it, back in 2020, here.
The GAO report notes that, although the IRST pod achieved initial capability on schedule in November 2024, including delivery of the first lot of low-rate initial production pods, a full-rate production decision has been delayed.
At one point, a determination on full-rate production was planned for January 2025, but this was missed 'due to delays incurred during flight testing.' As a result, the program has now breached its baseline schedule for the second time in three years.
'IRST officials told us that operational tests were delayed by two months due to software defects that caused IRST pods to falsely report overheating,' the GAO notes.
Director, Operational Test and Evaluation (DOT&E) officials told the GAO that the problem 'was relatively easy to fix and would likely have been addressed during developmental testing had the program allocated more time for that testing.'
Thanks to those operational testing delays, the publication of the DOT&E report that informs the full-rate decision production slipped until March 2025. A corresponding decision is now expected sometime this month.
Until then, the program is somewhat in limbo, although it has achieved some good results, notably demonstrating 'capability at tactically significant ranges during operational testing.'
This has been tempered, however, by how often the pods failed during that same testing.
DOT&E officials told the GAO that the pods were 'extremely unreliable.' While we previously knew of issues with reliability, today's report confirms just how bad these are. Although 'the program improved pod reliability as it made software updates, [it] only managed to achieve 14 hours mean time between operational mission failures — short of the 40 hours required.'
Not surprisingly, the DOT&E determined that deploying the IRST pods without improving their reliability would transfer risk to the Navy's fleet.
Of course, this is bad news for the Navy, and for the F/A-18E/F community specifically, with IRST sensors — which can detect and track objects from a distance and in environments where radar may be ineffective — is increasingly seen as a vital air combat tool.
Seemingly ever since it was first flown on a Super Hornet in late 2019, the IRST pod has faced issues.
A previous GAO report, in 2023, noted that 'between 20 and 30 percent of the manufactured components [in the IRST pod] failed to meet performance specifications due to microelectronics issues.' These problems persisted more than four years after limited manufacturing had begun and served to delay the launch of developmental and operational testing.
The same 2023 report also described how 'staffing challenges' at a critical software development contractor were leading to holdups in the program.
Then came a DOT&E report, which looked at the results of tests involving Infrared Optimized Configuration (IROC) pods, described as 'operationally equivalent' but designated for flight test. IROC pods were used for operational test and evaluation (IOT&E) between April and September 2024.
This report noted that 'operational test events were adversely affected by IRST Block II system reliability failures' and concluded that the pod 'demonstrated significant reliability problems.'
'Throughout the test period, IRST Block II suffered from hardware and software deficiencies, which required the aircrew to restart the pod multiple times,' the DOT&E report said. 'Troubleshooting and repair often exceeded the abilities of Navy maintenance crews and required assistance from Lockheed Martin.'
In the meantime, however, earlier iterations of the pod have already been deployed on operations, carried by Super Hornets in the Middle East, with photos emerging of this appearing in late 2020.
As the Navy awaits the decision on whether or not to pursue full-rate production, there's no doubt about the utility of an IRST pod — provided that it works.
The specific advantages of the IRST pod are something we have discussed before, including with the Super Hornet program manager:
'Very importantly, the IRST pod provides an entirely passive capability, relying exclusively on the infrared spectrum to detect and track airborne targets, including those at far beyond visual range. With no radio-frequency emissions, the target won't be alerted to the fact that they've been detected and are being tracked. At the same time, the IRST does not give away the location and presence of the host platform. This kind of sensor also provides a vital companion to the Super Hornet's AN/APG-79 radar, functions of which may well be compromised in a heavy electronic attack or radar-denied environment.'
Meanwhile, similar kinds of sensors have been found on fighters operated by potential adversaries for decades.
China and Russia operate tactical fighters such as the Su-35 and Su-30 Flanker series that incorporate IRST sensors as standard. In Western Europe, the Eurofighter Typhoon and Saab Gripen E, for example, also offer them.
Closer to home, the U.S. Air Force has already put equivalent sensors on its F-15Cs and F-16Cs, making the delays to the Navy's program all the more puzzling. On the other hand, we don't know exactly how reliable the Air Force's IRST pods are, and we do know that there are substantial differences between the Air Force and Navy versions, although they both use IRST21 as a base sensor.Still, the fact that a functioning IRST capability can be integrated on even older platforms without too much difficulty is also evidenced in the contractor-operated adversary community, which is increasingly flying fast jets with IRST sensors to better replicate potential threat aircraft. On the other hand, it should be recalled that not all IRST sensors offer the same level of capabilities, with significant differences also in terms of depth of integration and fusion between different types and aircraft, especially over time. This applies especially to the higher-end IRST pod for the Super Hornet and some of the cheaper off-the-shelf options that are now available.
Threat aircraft with IRST capabilities continue to proliferate, but so do the kinds of threat platforms for which a sensor of this kind would be most useful to counter.
China, especially, is making rapid developments in stealth technology and advanced electronic warfare, two areas that make the introduction of an IRST sensor all the more compelling. These kinds of infrared sensors are immune to radar-evading stealth technology and are not affected by electromagnetic jamming and other electronic attacks.
For Navy Super Hornets, a fully functional ISRT pod would help to detect and target advanced Chinese platforms in a future conflict in the Pacific theater.
At the same time, these pods can significantly boost the flight crew's situational air-to-air 'picture' in conjunction with more traditional sensors.
As noted previously, there has been some good news with the latest iteration of the IRST pod, specifically the fact that it has, in a test environment, demonstrated that it can detect targets at long ranges. Furthermore, it can translate this data into stable system tracks that would be suitable for weapons employment.
With its clear potential, it's certainly alarming for the Navy that it is still being kept waiting for the vital capabilities promised by the IRST pod.
Contact the author: thomas@thewarzone.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Yahoo

time3 hours ago

  • Yahoo

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease,2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults.3 This approval was supported by results from Moderna's Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATIONmRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: Have any allergies Had a severe allergic reaction after receiving a previous dose of any other vaccine Have a fever Have a bleeding disorder or are on a blood thinner Are immunocompromised or are on a medicine that affects your immune system Have received any other RSV vaccine Have ever fainted in association with an injection How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Side effects that have been reported in clinical trials with mRESVIA include: Injection-site reactions: pain, underarm swelling or tenderness in the same arm of the injection, swelling (hardness), and redness Fatigue, headache, muscle pain, joint pain, chills, nausea or vomiting, fever and hives These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media:Chris RidleyHead of Global Media Relations+1 Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

The Rare Earth Trap: How China Could Cripple America's Tech and Defense in One Move
The Rare Earth Trap: How China Could Cripple America's Tech and Defense in One Move

Yahoo

time3 hours ago

  • Yahoo

The Rare Earth Trap: How China Could Cripple America's Tech and Defense in One Move

China may not have Silicon Valley, but it controls the minerals that make Silicon Valley run. From electric motors to missile systems, rare earth elements are the silent backbone of modern techand Beijing owns the playbook. In 2024, China produced 270,000 tons of rare earthsabout six times more than the it dominates global refining. When trade tensions flared again, Beijing didn't just talk tough. It added seven rare earths to its export control list, causing headaches for American manufacturers. Tesla (TSLA) flagged rare-earth magnet shortages as a bottleneck for its humanoid robot, while Ford was forced to idle a major Chicago plant due to supply disruptions. Warning! GuruFocus has detected 6 Warning Sign with MP. The pressure doesn't stop at consumer goods. The F-35 fighter jet alone requires over 900 pounds of rare earths. And yet, the U.S. has just one major rare-earth mineMP Materials' (NYSE:MP) Mountain Passand almost no refining capacity. Trump, aiming to break China's chokehold, invoked emergency powers in March to accelerate domestic mining and processing. He followed up with an investigation into the national security risks of mineral imports, with recommendations expected within 270 days. Still, even fast-tracked projects could take years, and in the meantime, tariffs could drive up prices for the very materials U.S. companies depend on. China's control runs deep. It can approveor delayexport licenses without explanation, leaving global supply chains exposed. The message is clear: if the U.S. wants to restrict chip exports, China can slow-roll the magnets that drive EVs and missiles. Trump has floated Greenland and Ukraine as alternative sources, but neither has proven, scalable capacity. Rare earths aren't rarebut reliable supply chains are. And as the trade war evolves, the world is learning that dominance in materials might be more powerful than dominance in manufacturing. This article first appeared on GuruFocus.

Raytheon lands $646M Navy radar contract
Raytheon lands $646M Navy radar contract

Yahoo

time4 hours ago

  • Yahoo

Raytheon lands $646M Navy radar contract

ANDOVER — Defense contractor Raytheon has been awarded a $646 million contract to continue producing advanced maritime radars for the U.S. Navy. The radar, called the SPY-6, is one of several radar programs designed and manufactured at Raytheon's Radar Development Facility, 350 Lowell St. The 30,000, square-foot site is vertically integrated and highly automated and supports the production of different radars for U.S. and allied forces. The SPY-6 family of radars performs air and missile defense for seven classes of ships, according to Raytheon's website. The integrated radars have the ability to defend against ballistic, cruise and hypersonic missiles and hostile aircraft and surface ships simultaneously. This is the fourth option exercised from a hardware, production and sustainment contract in March 2022 that is valued up to $3 billion over five years. Three years ago, Raytheon won a $651 million radar contract with the Navy to outfit new surface ships with radar that can find and track enemy missiles and planes at the same time. Under this contract, Raytheon will provide the U.S Navy with four additional radars. This increases the total amount of radars under contract for procurement to 42. A majority of the work under the contract will take place in Andover through 2028. 'SPY-6 enables the U.S. Navy to see further than they've ever seen before, providing sailors with more time to respond to detected threats,' President of Naval Power at Raytheon Barbara Borgonovi said. 'This latest contract builds on our decades of experience and technical expertise in developing modular, scalable, and highly maintainable radars.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store